

A grayscale photograph of a surgical team in an operating room, viewed from above. The surgeons are wearing masks and caps, and are illuminated by large overhead surgical lights. The scene is dimly lit, with the primary light source being the circular surgical lamps.

# FluoGuide


**Maximizing surgical outcomes  
Making cancer fluorescent**

Life Science Investor Conference  
Økonomiske Ugebrev  
23 February 2022

# Forward looking statements

This presentation contains forward-looking statements that provide FluoGuide's expectations or forecasts of future events such as new product developments, regulatory approvals and financial performance. Such forward looking statements are subject to risks, uncertainties and may be impacted by inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of FluoGuide's forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, breaches or terminations of contracts, government-mandated or market driven price decreases, introduction of competing products, exposure to product liability claims and other lawsuits, changes in reimbursement rules, changes of laws regulations or interpretation thereof, and unexpected cost increases. FluoGuide undertakes no obligation to update forward looking statements.


# Cancer recur following surgery in half of patients



## Surgeons

- Risk that cancer recur
- Risk of damaging normal tissue
- Increased costs




Difficult to distinguish cancer from normal tissue






## Patients

- Lost lives
- Increased risk of disability
- Lost quality of life

# FG001 has game-changer potential in cancer treatment



# Simple solution, profound effect



# FG001 demonstrated safe and early evidence of efficacy

Safety and tolerability overview					
Cohort	Dosing	Dose (mg/pt)	Patients (#)	Ligth Seen (%)	Safety
1	morning	1	3	67%	Yes
2	morning	2	3	100%	Yes
3	morning	4	3	67%	Yes
4	morning	8	4	100%	Yes
5	morning	16	3	100%	Yes
5a	evening	16	5	100%	Yes
6	morning	24	3	100%	Yes
7	morning	36	3	100%	Yes
<b>Total</b>			<b>27</b>	<b>NA</b>	<b>Yes</b>

**FG001 appears useful for surgical guidance at doses of 8mg or higher**




# Unique technology relevant for 15 million patients with cancer annually

uPAR\*) is a protein involved in cancer invasion


- Highly specific for solid cancer
- Extensively expressed (>80%) on solid cancer types
- Expression in the **invasive front** of the cancer
- Expression **proportional with aggressivity** of the cancer and its invasive potential

More than 80% of solid cancers express uPAR



\*) uPAR (urokinase-type plasminogen activator receptor) is a **cell membrane** receptor that together with uPA focus the **proteolytic activity** of urokinase – leading to a highly localized **degradation of extracellular matrix**

















# Targets >5 billion USD market with current plans



Indication selection gives **short path to the market** and **large clinical potential**



# Unique technology well positioned

	First generation products Visible light - low tissue penetration (1-2 mm)	Second generation products Near Infra red light - deep tissue visibility (1-2 cm)	
	Untargeted and unspecific	Binds unspecific targets	Binds specifically to cancer
Development		     	   
Approved	   	 	

## Ideal profile

Targeted to cancer	Precise	✓
&		
Relevant for >80% of solid cancer	Large potential and high flexibility	✓
Near Infra red light	Deep visibility (1-2 cm)	✓
Equipment independent	Flexible and multiple partnerships	✓
Target has prognostic value	Provides additional value	✓

# Attractive pipe-line

	Pre-clinical	Phase I	Phase II	Phase III
<b>Brain cancer (FG001)</b>				
High grade glioma (incl. Glioblastoma)	Completed		2022	
Meningioma and low grade glioma	Completed		2022	
<b>Lung cancer (FG001)</b>				
NSCLC (Non small cell lung cancer)	Completed		2022	
<b>Pre-clinical development</b>				
FG002	Completed	2022		
<b>Research</b>				
Photothermal therapy (FG001)	2022			

**Completed**

2022

# Clear plan for FG001 in brain cancer

**Prioritize US filing and business development in rest of the world**

- Complete phase IIa trial in DK and SE
- Interact with FDA and EMA
- Obtain **scientific advice** from leading neurosurgeons
- **Market research** on price and reimbursement

**Incorporate into phase III & IV trial(s) and retain own US right**

Market for drugs guiding surgery >600 MUSD

Market for hardware >600 MUSD

USA >60% of market

Ample of unmet needs in oncological brain surgery

# Traded on Nasdaq First North Growth Market Stockholm - Ticker: FLUO

## Shareholder base

Retail investors  
approx. 40%

Institutional investors  
approx. 23% incl.  
Linc AB & Arbejdernes  
Landsbank

>9,000  
shareholders

Management  
and founders  
approx. 37%

## Research coverage

- ABG Sundal Collier
- SEB (commissioned)
- Redeye (commissioned)



# Delivered on promises and near-term significant milestones

Key achievement	2022	2023
<b>FG001</b> <ul style="list-style-type: none"><li>• Early evidence of efficacy ✓</li><li>• Safe and well tolerated ✓</li><li>• CTA for Phase II (FG001 / lung) ✓</li></ul>	<ul style="list-style-type: none"><li>• <b>Phase II efficacy data for FG001 in brain cancer</b></li></ul>	<ul style="list-style-type: none"><li>• <b>Phase II efficacy data for FG001 in lung</b></li></ul>
<b>Financial</b> <ul style="list-style-type: none"><li>• Incorporated in 2018, IPO'ed in 2019 ✓</li><li>• Best IPO in category ✓</li><li>• Attracted institutional investors ✓</li><li>• EIC funding MEUR 2.5 ✓</li></ul>	<ul style="list-style-type: none"><li>• <b>Phase II efficacy data for FG001 in meningioma and low grade glioma</b></li></ul>	<ul style="list-style-type: none"><li>• <b>Phase II efficacy data for FG001 in meningioma and low grade glioma</b></li></ul>
	<ul style="list-style-type: none"><li>• <b>Initiate manufacturing of FG001 for phase III trial</b></li></ul>	<ul style="list-style-type: none"><li>• <b>First FDA feedback for FG001 in brain</b></li></ul>
		<ul style="list-style-type: none"><li>• <b>Initiate Phase III in brain (FG001)</b></li></ul>
		<ul style="list-style-type: none"><li>• <b>Initiate IIb/III in lung cancer (FG001)</b></li></ul>
		<ul style="list-style-type: none"><li>• <b>Initiate phase I/II for FG002</b></li></ul>

# FluooGuide

Ticker: **FLUO**

[Fluoguide.com](https://fluoguide.com)